Clinical Trials Browser

Not yet recruiting × INDUSTRY × Lymphoma, Large B-Cell, Diffuse × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07424833 2026-02-20

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT07409428 2026-02-13

A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

Phase 3 Not yet recruiting

240 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07035379 2025-08-22

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Phase 1/2 Not yet recruiting

66 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06323447 2024-10-09

PC002

Not yet recruiting

210 enrolled

LymphoidPlasma cell

Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Phase 2 Not yet recruiting

100 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

BAF_FRontier-1

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

PC002

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP